Skip to main content

Advertisement

SpringerLink
Log in

Study of circulating antibodies against CD25 and FOXP3 in breast cancer

  • Research Article
  • Published:
Tumor Biology

Abstract

Our recent work suggests that circulating levels of anti-CD25 and anti-FOXP3 antibodies were significantly increased in patients with either lung cancer or esophageal cancer. To confirm if these two autoantibodies are specific for certain types of malignant tumors, the present work was thus undertaken to examine an alteration of anti-CD25 and anti-FOXP3 IgG levels in breast cancer. A total of 152 patients with breast cancer and 112 control subjects were recruited in this study. The levels of circulating anti-CD25 and anti-FOXP3 IgG antibodies were tested using an in-house enzyme-linked immunosorbent assay (ELISA). Student’s t test showed no significant differences in the levels of either anti-CD25 IgG or anti-FOXP3 IgG between patients with breast cancer and control subjects, although patients at stage I had increased levels of anti-CD25 IgG compared with control subjects (t = 2.11, P = 0.037); there was no significant association of the anti-FOXP3 IgG levels with stages of breast cancer. In conclusion, circulating IgG autoantibody to CD25 instead of FOXP3 may be a potential biomarker for early diagnosis of breast cancer but further investigation remains needed to replicate this initial finding.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Zhong L, Coe SP, Stromberg AJ, Khattar NH, Jett JR, Hirschowitz EA. Profiling tumor-associated antibodies for early detection of non-small cell lung cancer. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2006;1:513–9.

    Article  Google Scholar 

  2. Chapman C, Murray A, Chakrabarti J, Thorpe A, Woolston C, Sahin U, et al. Autoantibodies in breast cancer: their use as an aid to early diagnosis. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2007;18:868–73.

    Article  CAS  Google Scholar 

  3. Tan HT, Low J, Lim SG, Chung MC. Serum autoantibodies as biomarkers for early cancer detection. The FEBS journal. 2009;276:6880–904.

    Article  CAS  PubMed  Google Scholar 

  4. Lam S, Boyle P, Healey GF, Maddison P, Peek L, Murray A, et al. Earlycdt-lung: an immunobiomarker test as an aid to early detection of lung cancer. Cancer prevention research. 2011;4:1126–34.

    Article  PubMed  Google Scholar 

  5. Chapman CJ, Healey GF, Murray A, Boyle P, Robertson C, Peek LJ, et al. Earlycdt(r)-lung test: improved clinical utility through additional autoantibody assays. Tumor biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2012;33:1319–26.

    Article  CAS  Google Scholar 

  6. Piura E, Piura B. Autoantibodies to tailor-made panels of tumor-associated antigens in breast carcinoma. Journal of oncology. 2011;2011:982425.

    Article  PubMed Central  PubMed  Google Scholar 

  7. Ye H, Sun C, Ren P, Dai L, Peng B, Wang K, et al. Mini-array of multiple tumor-associated antigens (taas) in the immuno-diagnosis of breast cancer. Oncology letters. 2013;5:663–8.

    CAS  PubMed Central  PubMed  Google Scholar 

  8. Ye L, Li X, Sun S, Guan S, Wang M, Guan X, Lee KH, Wei J, Liu B: A study of circulating anti-cd25 antibodies in non-small cell lung cancer. Clinical & translational oncology: official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2012

  9. Ye L, Guan S, Zhang C, Lee KH, Sun S, Wei J, Liu B: Circulating autoantibody to foxp3 may be a potential biomarker for esophageal squamous cell carcinoma. Tumor biology: the journal of the International Society for Oncodevelopmental Biology and Medicine 2013

  10. Guan S, Liu B, Zhang C, Lee KH, Sun S, Wei J: Circulating autoantibody to cd25 may be a potential biomarker for early diagnosis of esophageal squamous cell carcinoma. Clinical & translational oncology: official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2013

  11. Redpath M, Xu B, van Kempen LC, Spatz A. The dual role of the x-linked Foxp3 gene in human cancers. Molecular oncology. 2011;5:156–63.

    Article  CAS  PubMed  Google Scholar 

  12. Olkhanud PB, Damdinsuren B, Bodogai M, Gress RE, Sen R, Wejksza K, et al. Tumor-evoked regulatory b cells promote breast cancer metastasis by converting resting Cd4(+) T cells to T regulatory cells. Cancer research. 2011;71:3505–15.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. DeSantis C, Siegel R, Bandi P, Jemal A. Breast cancer statistics, 2011. CA: a cancer journal for clinicians. 2011;61:409–18.

    Google Scholar 

  14. Autier P, Boniol M, La Vecchia C, Vatten L, Gavin A, Hery C, et al. Disparities in breast cancer mortality trends between 30 European countries: retrospective trend analysis of who mortality database. Bmj. 2010;341:c3620.

    Article  PubMed Central  PubMed  Google Scholar 

  15. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299:1057–61.

    Article  CAS  PubMed  Google Scholar 

  16. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of Cd4+Cd25+ regulatory T cells. Nature immunology. 2003;4:330–6.

    Article  CAS  PubMed  Google Scholar 

  17. Karanikas V, Speletas M, Zamanakou M, Kalala F, Loules G, Kerenidi T, et al. Foxp3 expression in human cancer cells. Journal of translational medicine. 2008;6:19.

    Article  PubMed Central  PubMed  Google Scholar 

  18. Wolf AM, Rumpold H, Wolf D, Gastl G, Reimer D, Jenewein N, et al. Role of forkhead box protein 3 expression in invasive breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007;25:4499–500. author reply 4500-4491.

    Article  Google Scholar 

  19. Merlo A, Casalini P, Carcangiu ML, Malventano C, Triulzi T, Menard S, et al. Foxp3 expression and overall survival in breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2009;27:1746–52.

    Article  CAS  Google Scholar 

  20. Ebert LM, Tan BS, Browning J, Svobodova S, Russell SE, Kirkpatrick N, et al. The regulatory T cell-associated transcription factor Foxp3 is expressed by tumor cells. Cancer research. 2008;68:3001–9.

    Article  CAS  PubMed  Google Scholar 

  21. Zhang HY, Sun H. Upregulation of Foxp3 inhibits cell proliferation, migration and invasion in epithelial ovarian cancer. Cancer letters. 2010;287:91–7.

    Article  CAS  PubMed  Google Scholar 

  22. Zuo T, Wang L, Morrison C, Chang X, Zhang H, Li W, et al. Foxp3 is an x-linked breast cancer suppressor gene and an important repressor of the Her-2/Erbb2 oncogene. Cell. 2007;129:1275–86.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated t cells expressing il-2 receptor alpha-chains (cd25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. Journal of immunology. 1995;155:1151–64.

    CAS  Google Scholar 

  24. Li CH, Kuo WH, Chang WC, Huang SC, Chang KJ, Sheu BC. Activation of regulatory T cells instigates functional down-regulation of cytotoxic T lymphocytes in human breast cancer. Immunologic research. 2011;51:71–9.

    Article  CAS  PubMed  Google Scholar 

  25. Erfani N, Mehrabadi SM, Ghayumi MA, Haghshenas MR, Mojtahedi Z, Ghaderi A, et al. Increase of regulatory T cells in metastatic stage and ctla-4 overexpression in lymphocytes of patients with non-small cell lung cancer (NSCLC). Lung cancer. 2012;77:306–11.

    Article  PubMed  Google Scholar 

Download references

Conflicts of interest

None

Funding

This study was supported by the fund of Heilongjiang Provincial Finance Department (Da Pang, grant no. 2011-14).

Author information

Authors and Affiliations

  1. Department of Breast Surgery, The Third Affiliated Hospital of Harbin Medical University, Harbin, 150040, China

    Tong Liu, Yan-ni Song, Qing-Yu Shi, Yang Liu, Xia-nan Bai & Da Pang

Authors
  1. Tong Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yan-ni Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Qing-Yu Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yang Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xia-nan Bai
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Da Pang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Da Pang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liu, T., Song, Yn., Shi, QY. et al. Study of circulating antibodies against CD25 and FOXP3 in breast cancer. Tumor Biol. 35, 3779–3783 (2014). https://doi.org/10.1007/s13277-013-1500-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-013-1500-x

Keywords

Search

Navigation